

Report of Introduction of New High-Cost Prescription Drug

Per 18 V.S.A. § 4637(d), the information below is limited to that which is in the public domain or publicly available.

Manufacturer Name	BeiGene USA, Inc. ("BeiGene")
Prescription Drug Name	BRUKINSA® (zanubrutinib)
Date of U.S. Product Launch	November 14, 2019
A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma ("MCL") who have received at least one prior therapy. BRUKINSA is approved for commercialization in the United States only. BeiGene has built a commercial team in the United States.
The estimated volume of patients who may be prescribed the drug	The estimated incidence of MCL in the United States is ~3,000 annually.
Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	BRUKINSA received accelerated approval from the FDA as a treatment for MCL in adult patients who have received at least one prior therapy.
The date and price of acquisition if the drug was not developed by the manufacturer	BRUKINSA was developed by BeiGene.